No fewer than five high-profile randomized phase II or III trials in this setting reported negative results in 2016, ranging from next-generation cytotoxic agents to novel immunotherapeutic approaches to molecularly targeted therapies. Thus, one could certainly not be faulted for feeling a jolt of enthusiasm upon hearing the positive study outcomes from ESPAC-4, reported by Neoptolemos and colleagues in The Lancet and reviewed in this issue of The ASCO Post. Read more . . .